Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection
Creator
Bloom, Jesse
Chu, Helen
Logue, Jennifer
Wolf, Caitlin
King, Neil
Casto, Amanda
Crawford, Katharine
Dingens, Adam
Eguia, Rachel
Fiala, Brooke
Pettie, Deleah
Shuey, Kiel
Wilcox, Naomi
Wrenn, Samuel
Source
MedRxiv
abstract
Most individuals infected with SARS-CoV-2 develop neutralizing antibodies that target the viral spike protein. Here we quantify how levels of these antibodies change in the months following SARS-CoV-2 infection by examining longitudinal samples collected between {approx}30 and 152 days post-symptom onset from a prospective cohort of 34 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about four-fold from one to four months post-symptom onset. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B-cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.
has issue date
2020-08-07
(
xsd:dateTime
)
bibo:doi
10.1101/2020.08.06.20169367
has license
medrxiv
sha1sum (hex)
80bad96abf3f205197f81de11b27050a829918d3
schema:url
https://doi.org/10.1101/2020.08.06.20169367
resource representing a document's title
Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection
resource representing a document's body
covid:80bad96abf3f205197f81de11b27050a829918d3#body_text
is
schema:about
of
named entity 'decline'
named entity 'accompanied'
named entity 'studies'
named entity 'infection'
named entity 'SARS-CoV-2'
named entity 'INFECTED'
named entity 'ABOUT'
named entity 'NECESSARY'
named entity 'SARS-CoV-2'
named entity 'titers'
named entity 'immunity'
named entity 'titers'
named entity 'asymptomatic'
named entity 'neutralizing antibody'
named entity 'This'
named entity 'initial'
named entity 'protein'
named entity 'declined'
named entity 'Title'
named entity 'SARS-CoV-2'
named entity 'neutralizing antibodies'
named entity 'viral infection'
named entity 'Neutralizing antibody'
named entity 'receptor'
named entity 'symptom'
named entity 'antibody'
named entity 'SARS-CoV-2'
named entity 'titer'
named entity 'questionnaire'
named entity 'SARS-CoV-2'
named entity 'symptom'
named entity 'IC50'
named entity 'transfected'
named entity 'area under the curve'
named entity 'Plasmid'
named entity 'centrifugation'
named entity 'antibody'
named entity 'symptom'
named entity 'Clinical data'
named entity 'Python'
named entity 'neutralizing antibody'
named entity 'CC-BY 4.0 International license'
named entity 'neutralizing antibody'
named entity 'IgG'
named entity 'antibody'
named entity 'antibodies'
named entity 'CC-BY 4.0 International license'
named entity 'Institutional Review Board'
named entity 'follow-up'
named entity 'symptom'
named entity 'IgM'
named entity 'plasma'
named entity 'horseradish peroxidase'
named entity 'plasma'
named entity 'symptom'
named entity 'antibodies'
named entity 'asymptomatic'
named entity 'asymptomatic infections'
named entity 'symptom'
named entity 'symptom'
named entity 'ELISAs'
named entity 'symptom'
named entity 'symptom'
named entity 'RBD'
named entity 'SARS-CoV-2'
named entity 'Neutralizing antibody'
named entity 'ELISAs'
named entity 'binding antibody'
named entity 'PBS'
named entity 'pseudotyped viruses'
named entity 'plasma'
named entity 'medRxiv'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 6
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software